Navigation Links
Omeros Announces Proposed Public Offering of Common Stock
Date:6/26/2012

SEATTLE, June 26, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced its intention to offer, subject to market and other conditions, shares of its common stock in a registered underwritten public offering. Omeros also expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering solely to cover overallotments, if any.

Omeros intends to use the net proceeds of the offering for general corporate purposes, including expenses related to the clinical development of Omeros' two ongoing Phase 3 clinical development programs – OMS302 for use during intraocular lens replacement procedures and OMS103HP for use during arthroscopic partial meniscectomy surgery.  The net offering proceeds may also be used to fund research and development in Omeros' preclinical studies and clinical trials, capital expenditures, working capital and to otherwise advance Omeros' product candidates toward commercialization.

Cowen and Company, LLC and Deutsche Bank Securities Inc. are acting as the joint book-running managers for the offering.

Omeros intends to offer and sell these securities pursuant to its existing shelf registration statement (File No. 333-169856), which was filed with the Securities and Exchange Commission on October 8, 2010 and declared effective on October 18, 2010. A prospectus supplement describing the terms of the offering will be filed with the Securities and Exchange Commission and will form a part of the effective registration statement. Copies of the prospectus supplement and accompanying prospectus relating to the offering may be obtained from Cowen and Company, LLC (c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, Phone: 631-274-2806, Fax: 631-254-7140), or Deutsche Bank Securit
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Omeros to Present at Jefferies 2012 Global Healthcare Conference
2. Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio
3. Omeros to Present at Deutsche Bank Securities Health Care Conference
4. Talyst Announces New Automated Medication Packager
5. Thermal Gradient Announces Manufacture of Next Generation DNA Testing Device
6. PrimeraDx Announces Commencement of Product Development Collaboration with Eli Lilly and Company
7. ADVENTRX Announces Manufacturing Agreement With Patheon to Manufacture ANX-188 Drug Product
8. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
9. Shire Announces that the US Food and Drug Administration has Responded to its Citizen Petition for Adderall XR and has Approved One Abbreviated New Drug Application for Generic Adderall XR
10. ERT Announces Stockholder Approval of Merger
11. Biodel Announces $18.5 Million Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... for Advanced Drug Delivery Systems -- Focus ... STUDY OBJECTIVES ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly ... and painless for patients to self-inject prescription drugs in the ... including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... grow to $220B by 2018, according to analysts.   Many of ...
(Date:1/14/2014)... North America,s leading business partnering event ... 30 th edition of its annual conference at the ... 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... specialty chemical companies will take part in the conference, which ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
(Date:7/9/2014)... signals active in almost all types of cancer sends ... may help fuel a tumour,s uncontrolled growth, new research ... London, identified a molecular trigger responsible for ratcheting up ... factory that makes the building blocks cancer cells need ... signalling pathway, called SREBP, controls the flow of messages ...
(Date:7/9/2014)... PROVIDENCE, R.I. Researchers have found that fecal ... difficile in immunocompromised patients. This is the result ... gastroenterologist in the Center for Women,s Gastrointestinal Medicine at ... have been published online in advance of print in ... Clostridium difficile , or C. diff , has ...
(Date:7/9/2014)... There has been a sharp increase in the ... using MyChart, the online, interactive service that allows patients ... healthcare providers, schedule appointments, and renew prescriptions. , Over ... MyChart each year increased five-fold, while the ... 10-fold, according to a study by Dr. David ...
(Date:7/9/2014)... Institute of Allergy and Infectious Diseases (NIAID), part ... an early-stage clinical trial of CRS3123, an investigational ... ( C. difficile ) infection. CRS3123 (previously ... inhibits C. difficile growth while sparing normal intestinal ... up to 30 healthy men and women ages ...
(Date:7/9/2014)... , , , , , ... , , , , ... assault rifle and the microphone is 50m downrange from the firer and approximately 30cm from the bullet... , ... , , , , , ... , , , , , , ...
Breaking Medicine News(10 mins):Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7
... MiddleBrook,Pharmaceuticals, Inc. (Nasdaq: MBRK ), a ... products, is scheduled,to announce its financial results for ... 2008, before the market opens. At 9:00 a.m. ... conference call to review the,Company,s third quarter financial ...
... The American Fertility Association,introduces Manicures and Martinis, ... women together in a casual setting over manicures ... preserving fertility. It,s,free, relaxing, fun, and educational. The ... hosted by leading professionals in the reproductive medical,field, ...
... TUCSON, Ariz., Oct. 30 NaturalNews.com, the ... one million health-conscious,consumers, has posted audio interviews ... of "Home Safe Home," and Byron Richards, ... nutritional supplement,provider. Both interviews are available as ...
... One of the Top 10 Most Interesting Metabolic ... 30 Genaera,Corporation (NASDAQ: GENR ) will ... held November 3-5 at the Lowes Hotel in,Philadelphia, ... Scientific Officer, will provide an overview on MSI-1436 ...
... are adjusted , , WEDNESDAY, Oct. 29 (HealthDay News) -- The ... it may pose problems more serious than adjusting sleep patterns. ... of heart attacks following the semi-annual one-hour time changes, although ... very first study on this topic and further studies are ...
... - Nuvo Research Inc.,(TSX: NRI), a Canadian drug development ... that are delivered to and through the skin,using its ... and operational results for the three and nine,months ended ... - The Company remains on target to ...
Cached Medicine News:Health News:MiddleBrook Pharmaceuticals Schedules Conference Call and Webcast for Third Quarter 2008 Financial Results 2Health News:The American Fertility Association Announces Plan to Help Young Women Preserve Fertility 2Health News:NaturalNews Posts Audio Interview with Consumer Chemical Expert Debra Lynn Dadd on Bisphenol-A 2Health News:Genaera to Present at Therapeutic Area Partnerships 2008 2Health News:Semi-Annual Time Changes May Affect the Heart 2Health News:Semi-Annual Time Changes May Affect the Heart 3Health News:NUVO announces third quarter 2008 financial results 2Health News:NUVO announces third quarter 2008 financial results 3Health News:NUVO announces third quarter 2008 financial results 4Health News:NUVO announces third quarter 2008 financial results 5Health News:NUVO announces third quarter 2008 financial results 6Health News:NUVO announces third quarter 2008 financial results 7Health News:NUVO announces third quarter 2008 financial results 8Health News:NUVO announces third quarter 2008 financial results 9Health News:NUVO announces third quarter 2008 financial results 10Health News:NUVO announces third quarter 2008 financial results 11Health News:NUVO announces third quarter 2008 financial results 12Health News:NUVO announces third quarter 2008 financial results 13Health News:NUVO announces third quarter 2008 financial results 14Health News:NUVO announces third quarter 2008 financial results 15
... The Vibratome 1500 Sectioning System provides a ... animal, or plant tissues. The 1500 ... sectioning without freezing or embedding. The ... the destruction of enzyme activities, and other ...
... The original Vibratome Semi-Automatic Tissue Sectioning ... rock solid tissue sectioning system. Researchers from ... Vibratome 1000 Classic for their fresh and ... 20 years. With the Vibratome ...
... Vibratome 3000 Plus Sectioning System provides a ... animal, or plant tissues. The 3000 ... sectioning without freezing or embedding. The ... the destruction of enzyme activities, and other ...
... Sectioning System provides a versatile means of ... tissues. The 1500 employs a vibrating ... or embedding. The creation of artifacts, ... enzyme activities, and other deleterious effect inherent ...
Medicine Products: